跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 74,950 条关于
“GLP-1/glucagon dual receptor agonist”
全部
74,950
临床试验
44,966
药物
9,220
机构
1,479
资讯
19,285
去年
MetaVia's Novel Dual Receptor Agonist Shows Promising 6.3% Weight Loss in Phase 1 Obesity Trial
去年
Altimmune's Pemvidutide Obesity Program Gains FDA Agreement on Phase 3 Design
去年
Altimmune Achieves FDA Agreement on Phase 3 Program for Pemvidutide in Obesity Treatment
去年
Altimmune Secures $100 Million Credit Facility to Advance Pemvidutide Development for MASH and Alcohol-Related Disorders
去年
Altimmune Appoints Linda Richardson as Chief Commercial Officer Ahead of Pemvidutide Phase 3 MASH Trial
去年
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide for MASH
去年
Innovent to Present Phase 3 Results of Dual GLP-1/Glucagon Receptor Agonist Mazdutide at ADA 2025
去年
Altimmune and MindMed Join Nasdaq Biotechnology Index, Anticipate Key Clinical Data in 2025
去年
OPKO Health and Entera Bio Collaborate to Develop First Oral GLP-1/Glucagon Dual Agonist for Obesity Treatment
11个月前
Chugai Licenses Roche's CT-388 Dual GLP-1/GIP Receptor Agonist for Japan Market
第 1 页，共 1929 页
上一页
下一页
